Safety, clinical activity and biomarker results from a phase lb study of erlotinib plus atezolizumab in advanced NSCLC Meeting Abstract
| Authors: | Rudin, C.; Cervantes, A.; Dowlati, A.; Besse, B.; Ma, B.; Costa, D.; Schmid, P.; Heist, R.; Villaflor, V.; Sarkar, I.; Huseni, M.; Foster, P.; O'Hear, C.; Gettingeril, S. |
| Abstract Title: | Safety, clinical activity and biomarker results from a phase lb study of erlotinib plus atezolizumab in advanced NSCLC |
| Meeting Title: | IASLC 17th World Conference on Lung Cancer |
| Keywords: | erlotinib; immunotherapy; nsclc; atezolizumab |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 12 |
| Issue: | 1 Suppl. |
| Meeting Dates: | 2016 Dec 4-7 |
| Meeting Location: | Vienna, Austria |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2017-01-01 |
| Start Page: | S1302 |
| End Page: | S1303 |
| Language: | English |
| ACCESSION: | WOS:000413055803090 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2016.11.1841 |
| Notes: | Meeting Abstract: P3.02c-046 -- Source: Wos |
